Gary L. Dillehay

Nuclear Medicine

675 N Saint Clair St Ste 8-110
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.

Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: March 17, 2023

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma.

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma.

Journal: Blood advances

Published: July 07, 2022

Potential Significant Changes in Nuclear Regulatory Commission Policies Regarding Training and Experience Requirements for the Use of Radiopharmaceuticals.

Potential Significant Changes in Nuclear Regulatory Commission Policies Regarding Training and Experience Requirements for the Use of Radiopharmaceuticals.

Journal: Journal of the American College of Radiology : JACR

Published: July 15, 2020

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.

Journal: Blood

Published: June 05, 2020

Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project.

Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 11, 2020

The Martinique Principles.

The Martinique Principles.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: June 23, 2019

Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association.

Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association.

Journal: Thyroid : official journal of the American Thyroid Association

Published: March 23, 2019

Training and Education Requirements for Authorized Users of Therapeutic Radiopharmaceuticals: Changes Under Consideration for 10CFR35.390 and Their Potential Impact.

Training and Education Requirements for Authorized Users of Therapeutic Radiopharmaceuticals: Changes Under Consideration for 10CFR35.390 and Their Potential Impact.

Journal: Journal of the American College of Radiology : JACR

Published: December 28, 2018

Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.

Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.

Journal: International journal of radiation oncology, biology, physics

Published: August 09, 2018

SNMMI comment on ASCO 2013 "Choosing wisely" recommendation on use of PET/CT in recurrent cancer surveillance.

SNMMI comment on ASCO 2013 "Choosing wisely" recommendation on use of PET/CT in recurrent cancer surveillance.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 26, 2014

F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.

F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.

Journal: British journal of haematology

Published: November 25, 2013

Advocating for appropriate and adequate reimbursement.

Advocating for appropriate and adequate reimbursement.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 05, 2013

Showing 1-12 of 16

Last Updated: 09/26/2026